

## Review

# Therapeutic implications of exosomes in the treatment of radiation injury

Shijie Dai<sup>1,†</sup>, Yuzhong Wen<sup>1,†</sup>, Peng Luo<sup>2</sup>, Le Ma<sup>2</sup>, Yunsheng Liu<sup>2</sup>, Junhua Ai<sup>\*,†</sup> and Chunmeng Shi<sup>2,\*,†</sup>

<sup>1</sup>Department of General Surgery, The First Affiliated Hospital of Nanchang University, Institute of Digestive Surgery, Nanchang University, Nanchang 330006, China; and <sup>2</sup>Institute of Rocket Force Medicine, State Key Laboratory of Trauma, Burns and Combined Injury, Third Military Medical University, Chongqing 400038, China

\*Correspondence. Junhua Ai, Email: [aijh0001@163.com](mailto:aijh0001@163.com); Chunmeng Shi, Email: [shicm@sina.com](mailto:shicm@sina.com)

†These authors contributed equally to this work.

Received 8 June 2021; Revised 11 November 2021; Editorial decision 11 November 2021

## Abstract

Radiotherapy is one of the main cancer treatments, but it may damage normal tissue and cause various side effects. At present, radioprotective agents used in clinics have side effects such as nausea, vomiting, diarrhea and hypotension, which limit their clinical application. It has been found that exosomes play an indispensable role in radiation injury. Exosomes are lipid bilayer vesicles that carry various bioactive substances, such as proteins, lipids and microRNA (miRNA), that play a key role in cell-to-cell communication and affect tissue injury and repair. In addition, studies have shown that radiation can increase the uptake of exosomes in cells and affect the composition and secretion of exosomes. Here, we review the existing studies and discuss the effects of radiation on exosomes and the role of exosomes in radiation injury, aiming to provide new insights for the treatment of radiation injury.

**Key words:** Exosome, Radiation injury, Treatment

## Highlights

- This article reviews the effects of radiation on the biological effects of exosomes and the role of exosomes in radiation-induced skin injury, radiation-induced lung injury and radiation-induced bone injury.
- Exosomes provide new insights for the treatment of radiation injury.

## Background

The source of radiation exposure is related to medical procedures, such as clinical diagnosis and radiotherapy, and industry activities [1]. Radiotherapy is one of the major cancer treatments. Although radiotherapy can improve the local control rate of tumours and patients outcomes, normal tissues often show radiation injury following radiotherapy [2].

Radiotherapy lead to various side effects, such as radiation-induced skin fibrosis, lung injury, bone loss, etc. In addition, radiation-induced bystander effects (RIBE) in unexposed tissues has shown phenomena similar to radiation exposure, such as apoptosis, gene instability, gene expression changes, chromosome breakage and mutations [3]. Serious injury can influence treatment and restrict the effective therapeutic dose

© The Author(s) 2022. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

for tumour control [4]. Therefore, urgent issues for cancer patients receiving radiotherapy include the ancillary antitumour effect and resistance to radiation injury [5]. The two main mechanisms that lead to radiation-induced tissue injury are direct DNA injury and reactive oxygen species (ROS) production [6]. Ionizing radiation (IR) absorbed by tissues affects molecules in cells. The absorbed energy gives rise to free radicals in the cells, most commonly ROS that are highly reactive. Excessive ROS leads to DNA injuries, such as simple base damage, DNA double-strand breaks (DSBs) or DNA crosslinks [7,8]. These injuries induce several cellular repair mechanisms, e.g. base excision repair and homologous recombination. However, if massive DNA injury is induced, these repair mechanisms fail, eventually leading to cell cycle arrest, senescence or cell death [9]. Thus, radiation-induced tissue injury has become a focus of prevention and treatment in biomedical studies. Amifostine (WR-2721) remains the only clinically approved broad-spectrum radioprotector that can clear out free radicals, protect DNA and accelerate repair [10]. However, the radioprotector's toxic side effects, such as nausea, vomiting, diarrhoea and hypotension [10,11], limit its clinical use.

In recent years, a growing number of studies have found that exosomes play a significant role in radiation injury, which has aroused great interest among researchers. With an average diameter of ~100 nm [12], exosomes are common membrane-bound nanovesicles that carry various bioactive substances, such as lipids, proteins and nucleic acids, which are involved in intercellular communication and cellular signal transduction and changes in cell or tissue metabolism [13]. In addition, exosomes are also involved in the immune response [14] and the rescue of apoptosis [15]. Furthermore, recent studies have reported the important role of exosomes in disease treatment, including cancer [16], cardiovascular diseases [17,18], neurodegenerative diseases [19] and tissue injury [20]. A number of clinical trials have confirmed the safety of using exosomes in humans for immunotherapy [21,22]. As cell-free therapeutic drugs, exosomes, as endogenous vesicles, usually do not cause an immune response when entering humans [23], so they are considered to be safer than cell therapy. Moreover, exosomes have almost no cytotoxicity and have better storage stability and antiserum aggregation ability [24]. In addition, exosomes can be stored stably for a long period at  $-80^{\circ}\text{C}$ . In regenerative medicine, exosomes may be more advantageous than stem cells because they avoid the challenges and limitations associated with stem cells [25]. It has been proved that the survival rate of transplanted stem cells in ischemic tissue is low [26]. Moreover, the risks of cell dedifferentiation, immune rejection and tumour formation further limits the direct application of stem cell transplantation for treatment [27]. Furthermore, because of their bilayer membrane and nanoscale size, exosomes can preserve their cargoes from removal or damage caused by complement binding or macrophages, extending their circulating half-life and increasing their biological activity [28]. Thus, exosomes as carriers have great application potential. Hazawa *et al.*


[29] found that radiation enhanced cell uptake of exosomes by forming the tetraspanin complex CD29/CD81, suggesting the potential role of exosomes in radiation injury. Furthermore, exosomal microRNA (miR-210) can regulate the transcription pattern of hypoxia-inducible factor-1 to promote a more effective repair of genomic DSBs, thereby enhancing the radioresistance of cells [30]. In this review, we discuss the effects of radiation on the biological effects of exosomes and the role of exosomes in radiation-induced skin, lung and bone injury, which provides new insights into the treatment of radiation injury.

## Review

### Exosomes

The term 'exosome' was put forward as early as the 1980s when exosomes were originally thought of as simple molecular trash cans for packaging and transporting waste components in cells [31]. Exosomes exist in various extracellular fluids, including urine, saliva, blood, plasma, amniotic fluid, breast milk, cerebrospinal fluid etc. [32–34]. They have a typical cup-shaped morphology with negative staining, but they are round when viewed by transmission electron microscope and cryo-electron microscope [35,36]. Furthermore, their secretion occurs naturally, and cellular stress and activation signals can regulate the related processes [37]. Previous studies have found that exosomes derived from B lymphocytes can induce antigen presentation effects while motivating T lymphocyte activity [38]. Ever since then, researchers have been extremely interested in the study of exosomes. Studies have found that exosomes isolated from diverse body fluids show significant morphological multiplicity, indicating subsets of exosomes with diverse functions and contents [39,40]. In one study, researchers analyzed and quantified the morphology of exosomes secreted by the human mast cell line HMC-1 through electron microscopy techniques and divided them into nine different categories [41].

**Secretion of exosomes** In MISEV2018, exosomes are proposed as a subtype of extracellular vesicles (EVs) [42]. Exosomes are endogenous extracellular lipid bilayer vesicles that can be secreted by almost all types of cells [28]. The process of exosome production includes the double invagination of the plasma membrane and the creation of intracellular multivesicular bodies (MVBs) carrying intraluminal vesicles (ILVs) [12] (Figure 1). The plasma membrane is invaginated for the first time to produce a cup-like structure, leading to the reformation of the early sorted endosomes (ESEs), which in some circumstances may be directly incorporated into the preexisting ESEs [12]. Furthermore the formation of ESEs increases with the help of the trans-Golgi network (TGN) as well as the endoplasmic reticulum [36,43]. ESEs can become late-sorting endosomes (LSEs) through inward invagination of the restrictive membrane of the endosome and finally generate MVBs, and MVBs contain multiple ILVs (future exosomes) [12]. Then through the fusion of MVBs



**Figure 1.** The effect of radiation on the biogenesis of exosomes. Exosomes originate from the invagination of the plasma membrane, forming ESEs, LSEs and finally forming MVBs containing multiple ILVs. The TGN and endoplasmic reticulum can promote the formation of ESEs. MVBs can fuse with the plasma membrane to free the contained ILVs as exosomes and fuse with lysosomes or autophagosomes to be degraded. Radiation can affect the production and secretion of exosomes, and the formation of tetraspanin complex CD29/CD81 increases after radiation, which leads to an increase in the uptake of exosomes by cells. ESEs early sorted endosomes, LSEs late-sorting endosomes, MVBs multivesicular bodies, ILVs intraluminal vesicles, TGN trans-Golgi network, TSAP6 tumour suppressor-activated pathway 6

to the plasma membrane and exocytosis, ILVs are finally secreted in the form of exosomes with a diameter of ~40–160 nm (average 100 nm) [12]. The density of exosomes in the sucrose gradient is 1.15–1.19 g/mL [44]. The MVBs can fuse with the plasma membrane to free the carried ILVs as exosomes and can be degraded by fusion with lysosomes or autophagosomes [36,45]. It is worth noting that the mechanism of MVB transport and fusion with the cell membrane is affected by some Rab guanosine triphosphatase (GTPase) proteins [46,47]. Besides, different cell types, cell states and culture environments may change the secretory mechanism of exosomes [48].

**Components of exosomes** According to high-throughput research, exosomes contain a large number of bioactive substances, such as proteins, metabolites, mRNA [23], miRNA [23] and other non-coding RNA [49], mitochondrial DNA [50], and so on (Table 1). In addition, three exosome databases (ExoCarta, EVpedia and Vesiclepedia) provide relevant internal molecular information [51–53]. The main protein constituents of exosomes include membrane transport proteins and fusion proteins (Rab GTPases, annexins and flotillins, etc.), as well as protein families mostly associated with lipid microdomains, such as integrins and tetraspanins (such as CD63, CD9, CD81 and CD82) and heat shock proteins (such as hsp70 and 90) [54–56]. Bellingham *et al.* [57] conducted a small RNA deep-sequencing analysis of

exosomes, which showed that exosomes carry various RNA species, including messenger RNA fragments, miRNA and other small non-coding RNA, retroviral RNA repeat regions, structural RNA, small interfering RNA, etc. In addition, it is found that the content of some miRNAs in exosomes is higher than that in cells, which indicates that some miRNAs can be specifically packaged in exosomes [23]. As far as lipid species are concerned, exosomes are rich in long acyl chains of saturated fats, which are often found in lipid raft components (e.g. cholesterol, ceramide, sphingomyelin as well as glycerol phospholipids) [58], so exosomes generally have more cholesterol, ceramide and sphingomyelin than the donor cells [59].

The miRNA and protein in exosomes can efficiently promote tissue injury repair [5]. Previous studies have demonstrated that metallothionein-2 transported by exosomes has anti-inflammatory effects on macrophages and mouse colitis models [53], and metallothionein-2 is a critical regulator of NF- $\kappa$ B signalling [60]. Moreover, miR-223-3p [61] and miR-126 [62,63] have been found to inhibit pro-inflammatory responses. Although there is an increasing number of reports about the composition of exosomes, the properties and functions of the molecules carried by exosomes under specific conditions need to be studied further.

**Diagnostic potential of exosomes** Exosomes are present in almost all biological fluids. The biogenesis of exosomes

**Table 1.** Components of exosomes

Content	Main components	References
Proteins	Membrane transport proteins	[54–56]
	Fusion proteins	
	Integrins	
	Transmembrane proteins, such as CD63, CD9, CD81, CD82	
	Heat shock proteins, such as hsp 70 and 90	
RNA	mRNA	[57]
	miRNA	
	Other small non-coding RNA	
	Structural RNA	
	siRNA	
Lipid	Retroviral RNA repeat regions	[58]
	Cholesterol	
	Ceramide	
	Sphingomyelin	
Mitochondrial DNA	Phospholipids	[50]

involves complicated extracellular and intracellular molecular cargo that can be used for diagnostic testing [12] and provide a non-invasive or minimally invasive diagnosis [34]. miRNA, protein and lipid of exosomes can serve as diagnostic markers [64]. The specific miRNAs carried in exosomes can diagnose cancer or indicate the potential prognosis [65]. There is increasing evidence that exosomes derived from tumours carrying miRNA can be considered biomarkers for early cancer diagnosis [66]. In addition, the application of exosomes as a diagnostic tool can also be used in neurodegenerative diseases [67], cardiovascular diseases [68,69], liver diseases [70], kidney diseases [71], lung diseases [72], etc. Recent studies have shown that miR-125b in serum exosomes can be used as a non-invasive diagnostic marker for the severity of asthma [73].

Radiation can affect exosome composition, which can be used as a diagnostic biomarker to predict the effect of radiotherapy in patients [74]. Some studies have shown that exosomal miR-339-5p can improve esophageal squamous cell carcinoma radiosensitivity by down-regulating Cdc25A [75]. By analyzing the proteins of urine and serum exosomes in irradiated mice, it was found that urine-derived exosomes can reflect radiation injury to the liver and gastrointestinal and genitourinary tracts, and serum-derived exosomes can indicate radiation-induced vascular injury and acute inflammation [76]. Combining the contents of exosomes such as protein, lipid, RNA and miRNA, a multi-component combination method using combinatorial markers can be used to reflect the different aspects of disease-generating exosomes (such as metabolites, RNA and protein content), which can potentially improve the specificity and sensitivity of the diagnosis provided by exosomes [12].

### Effects of radiation on exosomes

**The effect of radiation on exosome secretion** Research by Arscott *et al.* [77] showed that radiation enhanced the number of exosomes derived from glioblastoma cells and normal astrocytes. Furthermore, radiation can promote the release of exosomes derived from prostate cancer [78]. More and more evidence has shown that the release of exosomes induced by IR increases in a dose- and time-dependent manner, owing to the activation of additional pressure-induced exosome secretion pathways [78]. Researchers have explored several molecular mechanisms that influence exosome secretion (Figure 1). Previous studies have shown that induced secretion of exosomes in irradiated cells is regulated by tumour suppressor-activated pathway 6 (TSAP6) protein, and p53 regulates TSAP6 protein transcription, so the cellular state of this DNA damage response factor influences the composition and secretion rate of exosomes [79]. Lespagnol *et al.* [80] have proved that the production and secretion of exosomes are strictly regulated biological processes dependent on TSAP6. In human prostate cancer cell lines [78], human keratinocytes HaCaT cells [81] and breast epithelial cancer MCF7 cells [82], it was confirmed that the exosomes secretion rate of p53 active cells increased after irradiation. Recent studies have demonstrated that low-level laser irradiation at high power intensity enhances the secretion of endothelial exosomes by activating transcription factors associated with Wnt signalling and autophagy stimulation [83]. In addition, it was found that the mitogen-activated protein kinase (MAPK) signalling pathway can regulate the secretion of exosomes [84]. Future research needs to explore further the secretion mechanism and influencing factors of exosomes to reveal the mechanism of influence of radiation on exosome secretion.

**The effect of radiation on exosome composition** Regarding radiation-induced changes in the composition of exosomes, the current reports are mostly related to the proteome of exosomes. (Table 2). It was initially reported that B7-H3 (CD276) protein levels had risen in exosomes derived from irradiated prostate cancer cells [78]. By analyzing the exosomes secreted by FaDu cells derived from human squamous head and neck cell carcinoma, it was found that the proteins overexpressed in the exosomes of irradiated cells included those involved in transcription, translation, cell division and cell signal transmission [85]. In addition, the levels of connective tissue growth factor mRNA and insulin-like growth factor binding protein 2 protein carried by exosomes derived from irradiated glioblastoma were significantly increased [77]. Shen *et al.* [86] found that the expression level of 15 miRNAs in melanocyte-derived exosomes irradiated with ultraviolet B (UVB) was higher than that of melanocyte-derived exosomes not irradiated with UVB, confirming for the first time that UVB irradiation can enhance melanocytes' secretion of exosomes and change their exosomal miRNA profile. Analysis of the effect of radiation on the composition of exosomes released from various cell types and radiation

**Table 2.** Effects of radiation on the composition of exosomes

Source of exosomes	Radiation source	Changes in the composition of exosomes	Reference
Human prostate cancer cell	Ionizing radiation	Rise in level of B7-H3 (CD276) protein	[78]
Human squamous head and neck cell carcinoma (FaDu)	Ionizing radiation	Rise in proteins include proteins involved in transcription, translation, cell division and cell signal transmission	[85]
Human glioblastoma	Ionizing radiation	Rise in level of insulin-like growth factor binding protein 2 proteins and connective tissue growth factor mRNA	[77]
Human melanocyte	Ultraviolet B exposure	Rise in level of 15 miRNAs (miR4488, miR-320d, miR-7704 etc.)	[86]

patterns shows that radiation can affect the secretion of the exosome, and in particular its molecular composition.

**Radiation increases the cellular uptake of exosomes** Radiation exposure can affect the uptake of exosomes by cells (Figure 1). After being released into the extracellular environment, exosomes are absorbed by nearby and distant receptor cells to fulfill their regulatory functions. Exosome uptake includes at least three steps: binding to the cell surface, fusion with the plasma membrane and internalization of the receptor cell [87]. The interaction between exosomes with their receptors is through adhesion molecules and ligands situated on the surface of the bilayer membrane [88,89]. Then they are internalized, and their cargoes are released into the cell, where they perform their regulatory functions. Previous studies have shown that the uptake of exosomes by cells is enhanced in a radiation dose-dependent manner, whereas the uptake of exosomes by cells induced by radiation does not depend on the type of recipient cells [29]. Moreover the formation of the tetraspanin complex CD29/CD81 increases after radiation, resulting in increased uptake of exosomes by cells [29].

## Exosomes and radiation injury


### Exosomes and radiation-induced skin injury

*The influence of irradiation on the skin* The skin is the largest organ of the human body and performs a series of significant biological functions, such as regulating body temperature, sensory perception, excretion, absorption and immunologic functions. The cutaneous epithelium is a tissue with a high rate of dividing cells [90], so the skin is extremely susceptible to radiation injury. It has been pointed out that ultraviolet radiation has two effects: inducing cell ageing and transforming skin melanocytes into melanoma [91]. In addition, cutaneous radiation injury can also be classified as acute (early effect) and chronic (late effect). Marcu [92] revealed that early effects are more apparent in quickly proliferating tissues (e.g. skin and mucosa), while late effects occur in tissues with slow cell turnover. Types of acute cutaneous radiation injury include erythema, hyperpigmentation, dry desquamation, alopecia, moist desquamation and ulceration [93,94]. Chronic adverse effects tend to be underestimated

and include delayed ulcers, fibrosis, ischemia, atrophy and cutaneous malignant changes [94–96]. Accumulating studies have shown that late effects are related to an imbalance of proinflammatory and profibrotic cytokines [96]. On the other hand, the risk of non-melanoma skin cancer increases after several years of radiation exposure [97]. In particular, cancers developed from keratinocytes (basal cell carcinoma, keratoacanthoma and squamous cell carcinoma) are radiation-related skin tumours [98,99].

*The role of exosomes in radiation-induced skin injury* The role of exosomes in radiation-induced skin injury is summarized in Figure 2. Studies have shown that the proliferation and migration of skin fibroblasts affect the process of wound healing [100]. In the senescence of human dermal fibroblasts induced by IR, it was found that mmu-miR-291a-3p derived from embryonic stem cells (ESC) restrained cell senescence through the transforming growth factor- $\beta$  receptor 2 (TGF- $\beta$ R2) signalling pathway, and mmu-miR-291a-3p accelerated the healing process of a skin incision in aged mice [101]. In addition, mesenchymal stem cells (MSCs) play a crucial role in regenerative skin processes [102]. Increasing evidence has shown that the therapeutic activity of adult stem cells occurs partially through paracrine effects [103]. Exosomes are vital components that account for the paracrine action of MSCs [48,104]. Recent studies suggest some special roles of MSC-exosomal miRNAs in mediating epithelial recoveries, such as that of miR-135a in aiding epithelial cell migration by inhibiting expression of the gene encoding large tumour suppresser homolog 2 (LATS2) during skin wound healing [105] and that of miR-126 in activating the PI3K-Akt and MAPK pathways during cutaneous repair in a rat model of diabetes [106]. Furthermore, some studies have shown that NF-E2-Related Factor2 (Nrf2) knockdown suppressed the antioxidant capacities of MSC-exosomes *in vitro* and *in vivo*. Therefore, MSC-derived exosomes protect against oxidative stress-induced cutaneous injury by adaptive regulation of the Nrf2 defence system [107]. MSC-exosomes exert an immunomodulatory function, primarily by regulating the function of immune cells or changing their inflammatory cytokine secretion characteristics [108]. In the presence of interferon- $\gamma$  (IFN- $\gamma$ ) and tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ), MSCs produce





**Figure 2.** The role of exosomes in radiation-induced skin damage. Mmu-miR-291a-3p derived from ESCs can restrain cell senescence through the TGF- $\beta$ R2 signalling pathway and accelerate the healing process of skin incisions in elderly mice. MSC- exosomal miR-135a increases epithelial cell migration by inhibiting the expression of the gene encoding LATS2 during skin wound healing. MSC- exosomal miR-126 can activate PI3K-Akt and MAPK pathways and promote the skin healing process. MSC- exosomal miR-146 up-regulates the expression of M2- related genes (such as TRAF6 and IRAK1) by targeting NF- $\kappa$ B signals, and miR-34 targets Notch1 to inhibit transcriptional pro-inflammatory cytokines encoding M1-related genes, such as IL-6 and TNF- $\alpha$ . Plasma-derived exosomes can promote wound healing by enhancing the expression of radiation resistance-related genes and regulating cell proliferation and ferroptosis of fibroblasts after radiation. In nude mice with ultraviolet B-induced skin photoaging, the exosomes derived from HDF have anti-skin senescence properties by down-regulating TNF- $\alpha$  and up-regulating TGF- $\beta$ , causing the expression of type I procollagen to increase and the expression of MMP-1 to decrease observably. In a photoaging skin model of rats induced by ultraviolet B radiation, exosomes from adipose-derived stem cells increased the expression of type I collagen mRNA and decreased mRNA expression, including type III collagen, MMP-1 and MMP-3, thus significantly improving the photoinjury of skin. Irradiated HaCaT keratinocytes secrete exosomal miR-27a, which up-regulates the expression of miR-27a in bystander WS1 fibroblasts, resulting in decreased MMP-2 expression, which delays cell migration and increases ROS level, resulting in prolonged wound healing time. ESC embryonic stem cells, TGF- $\beta$ R2 transforming growth factor-beta receptor 2, MSC mesenchymal stem cell, LATS2 large tumour suppresser homolog 2, MAPK mitogen-activated protein kinase, TRAF6 tumour necrosis factor receptor-associated factor 6, IRAK1 interleukin-1 receptor associated kinase 1, IL6 interleukin 6, TNF- $\alpha$  tumour necrosis factor-alpha, TGF- $\beta$  transforming growth factor-beta, HDF human dermal fibroblast, MMP matrix metalloproteinase, ROS reactive oxygen species

exosomes that induce macrophages to transform from M1-to M2-like phenotype, and exosomal miRNAs are involved in this process, such as miR-146 and miR-34 [109]. Mechanistically, miRNA-146 upregulates the expression of M2-related genes [tumour necrosis factor receptor-associated factor 6 (TRAF6) and interleukin-1 receptor associated kinase 1 (IRAK1)] via targeting Nuclear factor-kappa B (NF- $\kappa$ B) signals [110], while miR-34 targets Notch1 to inhibit the transcription of genes encoding M1-related pro-inflammatory cytokines, such as interleukin (IL)-6 and TNF- $\alpha$  [111]. In addition, research has shown that MSC-exosomes also suppresses epithelial-mesenchymal transition (EMT) by reducing epithelial depletion due to transformation, thereby maintaining the integrity of the epithelium and inhibiting tissue fibrosis [112,113]. Recent research has shown that plasma-derived exosomes can promote the healing of irradiated wounds by intensifying the expression of radiation resistance-related genes and regulating the cell proliferation and ferroptosis of fibroblasts after radiation [114].

In nude mice with UVB-induced skin photoaging, exosomes derived from 3D cultured human dermal fibroblast spheres showed anti-skin senescence properties by down-regulating TNF- $\alpha$  and up-regulating TGF- $\beta$ , leading to an

observable increase in the expression of type I procollagen and a decrease in matrix metalloproteinase (MMP)-1 [115]. Furthermore, Liang *et al.* [116] found that in a photoaging skin model of rats induced by UVB radiation, the injection of exosomes from adipose-derived stem cells significantly reduced the epidermal thickness and enhanced the dermis thickness of the photoaging skin, reduced the ratio of the stratum corneum in the epidermis, increased the expression of type I collagen mRNA and also decreased the expression of mRNA, including type III collagen, MMP-1 and MMP-3, thus significantly improving the photoinjury of skin.

The RIBE is defined as a biological response in non-irradiated cells receiving signals from other cells directly exposed to IR [117]. Exosomes can be used as a means of intercellular communication. Irradiated HaCaT keratinocytes secrete exosomal miR-27a, which up-regulates the expression of miR-27a in bystander WS1 fibroblasts, resulting in decreased MMP2 expression, which delayed cell migration and increased ROS level [118]. In addition, Tan *et al.* [118] also observed that the wound healing time was prolonged and the epidermis was thickened in mice due to subcutaneous injection of exosomes derived from irradiated HaCaT

keratinocytes. Thus, it is suggested that RIBEs may play a potential role in wound healing. Therefore, how exosomal miRNAs affect bystander effects by targeting downstream genes needs further research [119]. Exosomes can promote skin cell proliferation and epithelial regeneration and participate in the immune regulation of damaged skin, thereby accelerating wound healing and delaying skin aging. However, the more extensive mechanisms of exosomes in radiation-induced skin injury need to be studied further.

### Exosomes and radiation-induced lung injury

*The influence of irradiation on the lung* The lung is one of the most sensitive organs to IR, and radiation-induced lung injury (RILI) is a familiar complication in thoracic tumour radiotherapy [4]. The influences of lung irradiation are typically divided into early radiation pneumonitis, occurring within days to a few weeks after radiotherapy, and late radiation-induced pulmonary fibrosis, occurring months to years after the radiotherapy, which includes tissue fibrosis, necrosis, atrophy and vascular damage [4,120]. Human alveolar epithelium comprises type I and types II lung cells, which account for 90 and 10% of alveolar cells [120]. It has been reported that radiation immediately induced EMT in type II alveolar epithelial cells through the extracellular regulated protein kinases (ERK)/glycogen synthase kinase-3 $\beta$  (GSK3 $\beta$ )/Snail signalling pathway [121]. Radiation can induce the production of ROS and nitrogen species (NGS), leading to DNA strand breaks and alveolar epithelial cell death [122]. In addition, the release of multiple cytokines is regarded as having a significant role in the pathogenesis of RILI [123,124], including proinflammatory cytokines such as IL-1 $\alpha$ , IL-1 $\beta$ , IL-3, IL-6, IL-7, TNF- $\alpha$  and pro-fibrogenic cytokines such as TGF- $\beta$ 1 [125]. The persistence of the inflammatory state can develop into irreversible late radiation lung fibrosis. Advanced radiation pulmonary fibrosis is a chronic, progressive and ultimately fatal interstitial lung disease with a poor prognosis and poor response to existing drug treatments [126]. The pro-fibrogenic cytokine TGF- $\beta$  is the primary driver of late radiation-induced pulmonary fibrosis. The increase in TGF- $\beta$  levels after radiotherapy is accompanied by elevated expression of the type IV collagen gene [127]. TGF- $\beta$  inhibits collagen catabolism by the stimulation of tissue inhibitors of metalloproteinases (TIMPs), which results in collagen accumulation and transformation of fibroblasts into myofibroblasts, further leading to increased expression of alpha-smooth muscle actin ( $\alpha$ -SMA) and lung structural remodelling [128]. In addition, the enhanced activity of TIMPs and reduced MMP activity results in excessive extracellular matrix deposition [129] and excess collagen [122]. Interestingly, numerous studies suggest that a massive infiltration of alveolar macrophages was also observed in the lung after radiation [130,131]. Macrophages and fibroblasts are activated by ILs, TGF, TNF and platelet-derived growth factors, leading to the secretion of high levels of ILs and TNF- $\alpha$  through activated macrophages. TNF- $\alpha$  mediates

radiation pneumonitis and fibrosis by inducing the expression of intercellular adhesion molecules and the production of prostaglandins, as well as other inflammatory mediators [132]. Moreover, Park *et al.* [133] showed that IR promotes EMT in lung epithelial cells by M2 macrophages secreting high levels of TGF- $\beta$ . These changes result in lung fibrosis, which further causes the loss of respiratory capacity, tissue atrophy and necrosis [134].

*The role of exosomes in radiation-induced lung injury* The toxic side-effects of radioprotectors, such as nausea, vomiting, diarrhoea and hypotension, limit their clinical use [10,11]. Biological growth factors and cytokines such as IL-7, IL-11, granulocyte-colony stimulating factor, macrophage-colony stimulating factor and keratinocyte growth factor have been used to mitigate radiation-induced injury. Nevertheless, the successful effects of these compounds are also limited [11]. Moreover, although lung transplantation is the most useful measure for treating radiation-induced pulmonary injury, it is limited due to the lack of available donated lungs and transplantation-related complications [135]. Therefore, we urgently need a more effective treatment strategy based on the pathological mechanism of RILI.

MSCs, as multipotent stem cells, can regulate inflammation reaction, facilitate survival and repair impaired resident cells and increase the regeneration of damaged tissues [136], indicating that MSCs are a promising drug candidate for the treatment of RILI. Bury *et al.* [137] found that MSC grafts significantly reduced the presence of pro-inflammatory macrophages and neutrophils, attenuated the innate inflammatory response and promoted bladder tissue regeneration. Indeed, growing evidence shows that the therapeutic effects of MSCs can be attributed to their capacity to secrete paracrine factors [138]. Exogenously used MSCs may exert their complex paracrine anti-inflammatory, anti-fibrosis and reproductive effects through the released EVs [139]. The release of various cytokines plays a major role in the pathogenesis of RILI, as mentioned above. Exosomes derived from MSCs can reduce the pro-inflammatory cytokines IL-1 $\beta$ , IL-6 and TNF- $\alpha$  and promote the production of high levels of anti-inflammatory IL-10 [140] (Table 3). In addition, researchers have found that mesenchymal stem cell-derived exosomes can enhance IL-10 and TGF- $\beta$ 1 in human peripheral blood mononuclear cells and facilitate the proliferation and immunosuppression of T lymphocytes. Xiong *et al.* [141] further revealed that T lymphocytes could promote EMT and accelerate the occurrence of radioactive pulmonary fibrosis, and the effect of  $\beta$ -catenin was a possible mechanism. Interestingly, the reports of Blazquez *et al.* [142] confirmed that exosomes derived from human adipose MSCs could suppress the differentiation and activation of T cells and decrease the production of IFN- $\gamma$  by stimulating T cells *in vitro*. Also, the work of Moon *et al.* [143] demonstrated that exosomes derived from lung epithelial cells deliver caspase 3 (a proapoptotic factor) and activate macrophages through Rho-related coiled-coil kinase I. Therefore, clearing away lung

**Table 3.** The role of exosomes in radiation-induced lung injury

Exosome source	Biological functions	Exosomes containing miRNAs	Immunoregulation effects	References
MSC	1.Reduce levels of the pro-inflammatory cytokines (IL-1 $\beta$ ,IL-6,TNF- $\alpha$ ) and promote the production of the anti-inflammatory IL-10.	miR-181c	Reduce levels of IL-1 $\beta$ ,TNF- $\alpha$ and induce high levels of IL-10 by targeting the TLR4/p65 signaling pathway.	[112, 137, 140, 150,152-154, 156]
	2. Enhance IL-10 and TGF- $\beta$ 1 in human peripheral blood mononuclear cells.	miR-let-7b	By targeting TLR4	
	3. Faciliate the proliferation and immunosuppression of T lymphocytes.	miR-21, miR-23a, miR-145	By targeting TGF- $\beta$ 2	
	4. Reduce the presence of pro-inflammatory macrophages and neutrophils.	miR-125b	By targeting Smad2	
	5. Protected type II alveolar epithelial cells against apoptosis by down-regulating serum amyloid A3 (SAA3).	miR-let-7c	By targeting TGF- $\beta$ R1	
	6. Inhibit the epithelial-mesenchymal transition(EMT).	miR-30b-3p	Protect type II alveolar epithelial cells	
BM-MSC	Reduced the rate of apoptosis and suppressed the production of ROS after oxidative stress injury.	miR-214	Alleviate cell oxidative stress damage	[113, 147]
Human adipose MSC	Suppress the differentiation and activation of T cells,and decrease the production of interferon- $\gamma$ by stimulated T cells.	-	-	[142]
Lung epithelial cells	Deliver caspase 3 (a pro-apoptotic factor) and activate macrophages through Rho-related coiled-coil kinase I.	-	-	[143]
Lung macrophages	Further aggravate lung damage by release IL-36 $\gamma$ .	-	-	[143]
Mouse mastocytes	Protect the recipient cells under oxidative stress by improving the resistance of the recipient cells to oxidative stress.	-	-	[144]

IL interleukin, TGF- $\beta$  transforming growth factor-beta, SAA3 serum amyloid A3, EMT epithelial-mesenchymal transition, TNF- $\alpha$  tumour necrosis factor-alpha, TLR4 toll-like receptor 4, TGF- $\beta$ R1 transforming growth factor-beta receptor 1, ROS reactive oxygen species

epithelial cell-derived exosomes from the blood can reduce lung injury *in vivo*. Similarly, exosomes derived from lung macrophages release IL-36 $\gamma$  (a pro-inflammatory cytokine), leading to bacterial lung injury. Bone marrow mesenchymal stem cell (BM-MSC)-derived exosomes observably reduced the rate of apoptosis and suppressed the production of ROS after oxidative stress injury [113]. Exosomes derived from mouse mastocytes under oxidative stress can protect the recipient cells by improving their resistance to oxidative stress [144]. Moreover, MSC-exosomes also inhibit the EMT, as previously described. EMT is critical in inducing tissue fibrosis, leading to pathological rather than functional restoration of injured tissue.

Accumulating studies have reported the changes of miRNA in lung cancer patients after radiotherapy [145,146], suggesting that miRNA may play a significant role in the pathological process of RILI. BM-MSC-derived exosomes can alleviate cell oxidative stress damage by releasing miR-214, but over-expression of miR-214 can further promote fibrosis [147]. Studies have shown that the use of MSC-derived

exosomal miRNAs can treat various inflammatory diseases by regulating levels of the pro-inflammatory cytokines IL-1 $\beta$ , IL-6, TNF- $\alpha$  and others [148]. Exosomal miR-146a can be a key regulator of the innate immune response to prevent the expression of several pro-inflammatory factors, including TNF- $\alpha$ , IL-6 and IFN- $\gamma$ , and direct the inflammatory response [149]. Similarly, MSC exosome-shuttled miR-181c can reduce levels of IL-1 $\beta$  and TNF- $\alpha$  and induce high levels of IL-10 by targeting the toll-like receptor 4 (TLR4)/p65 signalling pathway [150]. Moreover, enhancing the transcription of miR-146 in macrophages and monocytes can attenuate the activation of monocytes/macrophages and inhibit the response of pro-inflammatory macrophages, thereby suppressing NF- $\kappa$ B-mediated inflammation [151]. Indeed, growing evidence has suggested the modulation of expression levels of inflammatory cytokines in damaged tissue by MSC release of exosomal miRNAs, including miR-let-7b targeting TLR4 [152], miR-21, miR-23a and miR-145 targeting TGF- $\beta$ 2 [154], miR-125b targeting Smad2 [153] and miR-let-7c targeting TGF- $\beta$ R1 [154]. Recent



research shows that the highly abundant miRNAs shuttled by human umbilical cord mesenchymal stem cells play a significant role in preventing inflammation and fibrosis [155], strongly suggesting the potential of MSC-released miRNAs for RILI therapy. Furthermore, MSC-exosomes promote the proliferation and survival of alveolar epithelial cells. For example, in an acute lung injury model, exosomes from miR-30b-3p overexpressing MSCs protected type II alveolar epithelial cells from apoptosis by down-regulating serum amyloid A3 [156]. In general, exosomes alleviate radiation-induced lung injury mainly by decreasing cellular oxidative stress damage, inflammation and fibrosis.

### Exosomes and radiation-induced bone injury

*The influence of irradiation on bone* The bone marrow is highly sensitive to radiation and is the major site of injury in radiotherapy [157]. Radiation-induced bone marrow injury leads to myelodysplasia, which is due to the death of progenitor cells, resulting in the loss of functional cells [158]. Sub-lethal doses of radiation can lead to bone marrow suppression and cause immunosuppression in patients due to abnormal numbers of functional blood cells. High doses of radiation can cause bone marrow failure. Radiation directly affects the differentiation potential of BM-MSCs and hematopoietic stem cells (HSCs) [159], leading to an overall decrease in the number of cells in the bone marrow and changes in bone marrow phenotypic composition [158]. This will not only cause immune system impairment but also weaken bone architectural quality. The bone marrow is an important part of the bone microenvironment because it produces MSCs and HSCs, which can be differentiated into osteoblasts (OBs) and osteoclasts (OCs), respectively [160]. EVs derived from mouse BM-MSCs can alleviate the radiation injury of bone marrow hematopoietic cells; EVs derived from endothelial cells can improve bone marrow cellularity, HSC and progenitor cell content in irradiated mice (reviewed in [161]). MSC-exosomes can repair radiation-induced hematopoietic system injury (reviewed in [5]). In bone, the tight regulation between bone formation by OBs and bone resorption by OCs is indispensable to maintain a functional skeletal system [162]. At a cellular level, OBs and adipocytes originate from the same progenitor cells, BM-MSCs, and can differentiate into various cell lineages [163]. Different from OBs, OCs are derived from HSCs in the bone marrow [159]. Numerous studies suggest that high IR doses primarily have deleterious effects on the bone, increasing bone resorption and decreasing bone formation [159]. Previous studies have shown that radiation-induced bone injury is mainly caused by defects in OBs that form bone. In addition, IR was reported to induce cell cycle arrest in OBs [164].

As BM-MSCs exhibit self-renewal capacity, high proliferative and various differentiation potentials are critical in bone recovery following irradiation, to maintain homeostasis with osteogenesis and adipogenesis under physiological conditions [165]. Results in earlier studies have shown that expression

of runt-related transcription factor-2 (RUNX2) and osterix transcription factor are the major determinants for the osteogenic differentiation of BM-MSCs, and the peroxisome proliferator-activated receptor- $\gamma$  (PPAR- $\gamma$ ) transcription factor and the CCAAT/enhancer-binding protein family are vital factors driving the adipogenic differentiation of BM-MSCs [166,167]. Wang *et al.* [168] revealed that the expression levels of RUNX2, alkaline phosphatase (ALP) and osteocalcin were decreased following irradiation, but no obvious changes in the gene and protein expression levels of PPAR- $\gamma$  were observed following irradiation. Therefore, BM-MSCs preferentially differentiate into adipocytes rather than OBs after irradiation, which finally results in fat accumulation and bone loss [169].

*The role of exosomes in radiation-induced bone injury* BM-MSCs play a significant role in maintaining bone homeostasis, and altered proliferation and differentiation of BM-MSCs is one major reason for irradiation-induced bone loss [165,170]. In recent years, researchers have sought to discover how to decrease the injury to BM-MSCs and restore their differentiation capacity in order to alleviate irradiation-induced bone loss. Research has shown that BM-MSC-derived microvesicles/microparticles and exosomes could reinduce the expression of chondrocyte markers (type II collagen, aggrecan) in osteoarthritis-like chondrocytes and suppress catabolic [MMP-13 and recombinant a disintegrin and metalloproteinase with thrombospondin 5 (ADAMTS5)] and inflammatory (inducible nitric oxide synthase) markers [171]. Exosomes and microvesicles/microparticles were also shown to protect chondrocytes from apoptosis and suppress macrophage activation [172].

Exosomes are special secretory vesicles involved in the paracrine effects of MSCs, and research has demonstrated that exosomes play a repairing role to the same extent as mesenchymal stem cell transplantation (MSCT) [28,173]. In healthy [174] and osteoporotic [175] animals, exosomes have also been shown to stimulate stem cell differentiation [176] and facilitate the repair of bone defects. Zhang *et al.* [174] demonstrated that exosomes could markedly promote human bone marrow-derived mesenchymal stem cell (HBM-MSC) osteogenic differentiation through activating the PI3K/Akt signalling pathway. Zuo *et al.* [113] revealed that MSCT and exosomes derived from BM-MSC transplantation could reverse bone loss in rats following irradiation, and exosomes can alleviate radiation-induced injury and accelerate DNA repair in BM-MSCs after irradiation. Exosomes alleviate radiation-induced oxidative stress in BM-MSCs by increasing the expression of antioxidant-related proteins, such as catalase, superoxide dismutase 1 (SOD1) and SOD2. In addition, the study also found that exosomes can restore the balance of adipogenesis and osteogenesis in irradiated BM-MSCs through activating the Wnt/ $\beta$ -catenin signalling pathway [113] (Table 4). BM-MSCs start differentiation after irradiation, but the differentiation tendency towards adipocytes exceeds that of OBs, and

**Table 4.** The role of exosomes in radiation-induced bone injury

Exosome source	Effects on irradiation of bone tissue	Exosomes containing miRNAs	Biological functions	References
BM-MSCs	1. Alleviate radiation-induced oxidative stress in BM-MSCs by increase the expression of antioxidant-related proteins (catalase,SOD1,SOD2).	miR-let-7	Supress the adipogenesis of hBM-MSC by regulating the expression of HMGA2 gene, thereby promoting bone formation.	[113, 177-180]
	2. Accelerate DNA repair in BM-MSCs after irradiation.	miR-218	Accelerates osteoblast differentiation and mineralization through Wnt signaling.	
	3. Restore the differentiation potential of irradiated BM-MSCs.	miR-199b	Involved in the regulation of osteoblast differentiation by Runx2.	
	4. Restore the balance of adipogenesis and osteogenesis of irradiated BM-MSCs by activating the Wnt/ $\beta$ -catenin pathway.	miR-885-5p	Inhibits osteogenic differentiation by targeting RUNX2.	
		miR-181a	Inhibit TGF- $\beta$ signaling molecules through suppressing T $\beta$ R-I/ Alk5 and promotes osteoblast differentiation and mineralization.	
BM Stromal cells	Promte the bone remodeling process by increasing osteoblast differentiation and mineralization.	-	-	[182]
Mature osteoblasts	Promoted bone growth by up-regulating RUNX2 and alkaline phosphatase, as well as strengthened matrix mineralization.	miR-677-3p	Promotes MSC osteogenic differentiation via targeting axis inhibition protein 1.	[184-186]
		miR-378	Improves the glucose-mediated osteogenic differentiation through activating PI3K/Akt signaling pathway.	
		miR-335-5p	Enhances osteoblast differentiation and mineralization by reduce the expression of DKK-1.	

BM-MSCs bone marrow mesenchymal stem cells, SOD superoxide dismutase, HMGA2 high-mobility group A2, RUNX2 runt-related transcription factor-2, TGF- $\beta$ R1/ALK5 transforming growth factor-beta receptor type I, MSCs mesenchymal stem cells, DKK-1 dickkopf-1

BM-MSC-derived exosome transplantation could restore the differentiation potential of irradiated BM-MSCs [113]. Because of its higher safety, low immunogenicity and easier storage, delivery and management, exosome therapy is a better option than MSC transplantation [13]. Moreover, the research of Xu *et al.* [177] revealed the presence of miRNAs in exosomes during BM-MSC osteogenic differentiation. They found that miR-218, miR-let-7a, miR-299-5p, miR-148a, miR-199b, miR-219 and miR-302b were up-regulated in exosomes derived from BM-MSCs. Nevertheless, miR-221, miR-155, miR-885-5p, miR-181a and miR-320c were markedly down-regulated in exosome specimens [177]. Mechanistically, miRNA and miR-let-7 can suppress the adipogenesis of HBMSCs by regulating the expression of the high mobility group A2 (HMGA2) gene, thereby promoting bone formation [178]. It has been reported that miR-218 can accelerate the osteogenic differentiation and mineralization of human adipose tissue stem cells by activating the Wnt/ $\beta$ -catenin signalling pathway [179]. MiR-885-5p expression down-regulates osteoblast activity by targeting RUNX2 [177]. miR-199b is also involved in the regulation of OB differentiation by RUNX2 [178]. miR-181a inhibits TGF- $\beta$  signalling molecules through suppressing TGF- $\beta$ R1/ALK5 and promotes OB differentiation and mineralization [180]. Furthermore, it has been found that exosomal miR-130b is overexpressed in both osteogenic and chondrogenic MSCs, indicating that miR-130b plays a vital role in the osteogenic and chondrogenic differentiation of MSCs [181].

The recent work, Behera and Tyagi [182] reported that exosomes derived from bone marrow stromal cells could promote the bone remodelling process by increasing OBs. Bone morphogenetic protein 9, growth factors and TGF- $\beta$ 1 existing in exosomes derived from bone marrow cells can facilitate osteogenic differentiation [183]. In addition, exosomes from mature OBs also accelerated bone growth by enhancing RUNX2 and ALP and strengthened matrix mineralization [184]. Previous research also confirmed that miR-335-5p enhances OB differentiation and mineralization by reducing the expression of dickkopf-1 (DKK-1) [185]. Recent research shows that exosomal miRNAs are produced through OB mineralization and accelerate osteogenic differentiation [182]. MiR-677-3p enhances the expression of axis inhibition protein 1 and improves MSC osteogenic differentiation [184]. MiR-378 improves glucose-mediated osteogenic differentiation by activating the PI3K/Akt signalling pathway [186]. In radiation-induced bone injury, exosomes can restore the differentiation potential of BM-MSCs, alleviate oxidative stress and accelerate DNA repair, thus promoting osteogenic differentiation and repair of bone defects.

#### Prospects and challenges of exosomes in radiation injury

At present, medical radiation countermeasures can be divided into three categories: radioprotective agents delivered before radiation exposure, radiation mitigators given shortly after radiation exposure but before the appearance of radiation

symptoms and therapeutics applied after the onset of symptoms [187]. The Food and Drug Administration (FDA) approved amifostine as a radioprotector and chemoprotector in 1995 [188], which should be used before or at the time of radiation [189]. Amifostine is a free-radical scavenger, which can protect cells from IR damage when used before radiation exposure. Preclinical studies have shown that amifostine selectively protects normal cells, mainly by scavenging free radicals, accelerating the recovery of damaged DNA by donating hydrogen and inducing hypoxia in cells [188]. Amifostine has a good radioprotective effect. However, its application is severely limited because of its short half-life, delivery by injection, the lack of an oral formulation, poor compliance and severe adverse effects, including nausea, vomiting, hypotension and allergic reactions [190,191]. As the risk of radiation exposure increases, the development of new radioprotectors is essential. The therapeutic application of exosomes has great potential. Furthermore, the delivery of biologically active substances from exosomes to receptor cells effectively changes their biological responses. In radiation-induced injury, exosomes have been shown to play a non-negligible role in treating and preventing tissue injury, providing new insights for the treatment of radiation injury. However, in other radiosensitive organs such as the intestine and salivary gland, the role of exosomes needs further research. The high self-renewal rate of intestinal stem cells leads to the intestinal epithelium being highly sensitive to radiation [192]. Radiation-induced gastrointestinal syndrome is the result of a combination of direct cytotoxic effects on the intestinal crypt and endothelial cells and subsequent loss of the mucosal barrier, leading to microbial infection, diarrhea, electrolyte imbalance, septic shock and systemic inflammatory response syndrome [193,194]. Recent studies have shown that macrophage-derived EV-packaged WNTs are critical for intestinal anti-radiation regeneration, which can reduce the radiation injury of intestinal epithelial cells and induce intestinal epithelial repair [192,195]. In addition, EVs derived from MSCs can reduce intestinal toxicity, promote epithelial repair and regeneration and maintain intestinal epithelium structural integrity in a mouse model of acute radiation syndrome [196]. Radiotherapy is the main treatment for head and neck cancer, but >75% of patients experience salivary gland niche destruction, salivary gland dysfunction and xerostomia after radiotherapy [197]. Because the salivary glands proliferate slowly and are composed of highly differentiated cells, they are sensitive to radiation [198]. Lombaert *et al.* [199] showed that salivary gland stem cell transplantation could rescue radiation-impaired salivary gland function. Transplantation of MSCs from bone marrow [200] and adipose tissue [201] can restore the morphology and function of the salivary glands in irradiated glands. In recent years, great progress has been made in research on a regeneration strategy for xerostomia. However, there are few reports on the role of exosomes in radiation-induced salivary gland injury, which needs to be further explored by researchers.

MSC-derived exosomes showed high safety in the treatment of refractory graft vs. host disease, repeated injections were well tolerated and no side effects were found [202]. Compared with cell therapy, exosomes have attractive advantages. Exosomes are considered the best candidates for cell-free therapy due to their ease of operation (resistant to freezing and thawing), high biological permeability and non-obvious immune rejection, and more importantly, their ability to cross the blood–brain barrier [28,203,204]. In addition, unlike fragile living cells, exosomes have a double-layer lipid structure that can maintain biological activity even after repeated manipulations [203]. Microvascular plugging or loss of transplanted cell viability hinders cell therapy, which is not a problem for exosome therapy [205]. Exosomes can be designed to deliver different therapeutic effective loads to the desired targets, such as short interfering RNA and chemotherapeutic drugs and immunomodulators [12]. Exosomes have good biocompatibility and can avoid being taken up by the reticuloendothelial system, which protects the encapsulated drug until it is delivered to the targeted site [19,206,207]. In addition, their bioavailability and ability to cross the blood–brain barrier makes exosomes promising carriers [208]. However, exosomes as the delivery vehicle for therapy need to be targeted. The components of exosomes derived from diverse cells are different, and their potential biological functions are also different. At present, most research on exosomes is still focused on protein classification, but their main function may be related to RNA delivery, so determining the mechanism of RNA sorting is beneficial to various applications of exosomes [28]. Moreover, research on the function of exosomes needs to be verified by more *in vivo* experiments.

In addition, the instability of the exosome contents is also an urgent problem. Some research has shown that the irradiation dose, as well as the pH value of the culture medium, can affect the number of miRNAs loaded in the exosome [209,210], and there is still a lack of unified standards for purification and quantification of exosomes from conditioned medium. The need to accurately describe exosomes will continue to rise as our understanding of the heterogeneity of exosomal cargo and function increases. The identification and isolation of single exosomes will substantially increase our understanding of the biological function of exosomes [12]. Therefore, we need to formulate more standardized purification techniques and analytical methods to study exosomes, and provide a theoretical basis for the correlation between exosomes and radiation injury and the application of exosomes in treatment and diagnosis.

## Conclusions

Exosomes are vital for intercellular communication and have a lot of promise for repairing radiation injury. As indicated above, in radiation-induced injury, exosomes can stimulate cell proliferation and regeneration, relieving cellular oxidative stress damage and regulating inflammatory responses and

enhancing differentiation. Although there are some challenges in the clinical application of exosomes, as they receive increasing attention, researchers will gain a deeper understanding of exosomes, which will provide new ideas for their use in the treatment and prevention of radiation injury.

### Conflicts of interest

None declared.

### Authors' contributions

SD and YW contributed equally to the review and should be viewed as co-first authors; they drafted and revised the manuscript. PL, LM and YL contributed to helpful discussion and reviewed the manuscript. JA and CS conceived and designed the manuscript, supervised the project and constantly gave invaluable feedback. All authors read and approved the final manuscript.

### Acknowledgements

This work was supported by the Key Program of National Natural Science Foundation of China (82030056), the National Key Research and Development Program (2016YFC1000805) and Intramural Research Project Grants (AWS17J007 and 2018-JCJQ-ZQ-001).

### References

1. Flynn DF, Goans RE. Nuclear terrorism: triage and medical management of radiation and combined-injury casualties. *Surg Clin North Am.* 2006;86:601–36.
2. Li S, Shao L, Xu T, Jiang X, Yang G, Dong L. An indispensable tool: exosomes play a role in therapy for radiation damage. *Biomed Pharmacother.* 2021;137:111401.
3. Tuncay Cagatay S, Mayah A, Mancuso M, Giardullo P, Pazzaglia S, Saran A, et al. Phenotypic and functional characteristics of exosomes derived from irradiated mouse organs and their role in the mechanisms driving non-targeted effects. *Int J Mol Sci.* 2020;21:8389.
4. Graves PR, Siddiqui F, Anscher MS, Movsas B. Radiation pulmonary toxicity: from mechanisms to management. *Semin Radiat Oncol.* 2010;20:201–7.
5. Pu X, Ma S, Gao Y, Xu T, Chang P, Dong L. Mesenchymal stem cell-derived exosomes: biological function and their therapeutic potential in radiation damage. *Cell.* 2020;10:42.
6. Azzam EI, Jay-Gerin JP, Pain D. Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury. *Cancer Lett.* 2012;327:48–60.
7. Green DE, Adler BJ, Chan ME, Rubin CT. Devastation of adult stem cell pools by irradiation precedes collapse of trabecular bone quality and quantity. *J Bone Miner Res.* 2012;27:749–59.
8. Hou J, Han ZP, Jing YY, Yang X, Zhang SS, Sun K, et al. Autophagy prevents irradiation injury and maintains stemness through decreasing ROS generation in mesenchymal stem cells. *Cell Death Dis.* 2013;4:e844.
9. Lowe DJ, Herzog M, Mosler T, Cohen H, Felton S, Beli P, et al. Chronic irradiation of human cells reduces histone levels and deregulates gene expression. *Sci Rep.* 2020;10:2200.
10. Rajan Radha R, Chandrasekharan G. Pulmonary injury associated with radiation therapy - assessment, complications and therapeutic targets. *Biomed Pharmacother.* 2017;89:1092–104.
11. Arora R, Gupta D, Chawla R, Sagar R, Sharma A, Kumar R, et al. Radioprotection by plant products: present status and future prospects. *Phytother Res.* 2005;19:1–22.
12. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. *Science.* 2020;367:eaa6977.
13. Phinney DG, Pittenger MF. Concise review: MSC-derived exosomes for cell-free therapy. *Stem Cells.* 2017;35:2103.
14. Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. *Nat Rev Immunol.* 2014;14:195–208.
15. Miksa M, Wu R, Dong W, Komura H, Amin D, Ji Y, et al. Immature dendritic cell-derived exosomes rescue septic animals via milk fat globule epidermal growth factor-factor VIII. *J Immunol.* 2009;183:5983–90.
16. Munson P, Shukla A. Exosomes: potential in cancer diagnosis and therapy. *Medicine.* 2015;2:310–27.
17. Feng Y, Huang W, Meng W, Jegga AG, Wang Y, Cai W, et al. Heat shock improves Sca-1+ stem cell survival and directs ischemic cardiomyocytes toward a pro-survival phenotype via exosomal transfer: a critical role for HSF1/miR-34a/HSP70 pathway. *Stem Cells.* 2014;32:462–72.
18. Khan M, Nickoloff E, Abramova T, Johnson J, Verma SK, Krishnamurthy P, et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. *Circ Res.* 2015;117:52–64.
19. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhani S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. *Nat Biotechnol.* 2011;29:341–5.
20. Tan C, Lai R, Wong W, Dan Y, Lim S-K, Ho H. Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. *Stem Cell Res Ther.* 2014;5:76.
21. Vader P, Mol EA, Pasterkamp G, Schiffelers RM. Extracellular vesicles for drug delivery. *Adv Drug Deliv Rev.* 2016;106:148–56.
22. Dai S, Wei D, Wu Z, Zhou X, Wei X, Huang H, et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. *Mol Ther.* 2008;16:782–90.
23. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol.* 2007;9:654–9.
24. Lu M, Zhao X, Xing H, Xun Z, Zhu S, Lang L, et al. Comparison of exosome-mimicking liposomes with conventional liposomes for intracellular delivery of siRNA. *Int J Pharm.* 2018;550:100–13.
25. Baglio SR, Pegtel DM, Baldini N. Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy. *Front Physiol.* 2012;3:359.
26. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. *Nature.* 2004;428:668–73.
27. Jeong JO, Han JW, Kim JM, Cho HJ, Park C, Lee N, et al. Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in



- experimental myocardial infarction and diabetic neuropathy. *Circ Res*. 2011;108:1340–7.
28. He C, Zheng S, Luo Y, Wang B. Exosome Theranostics: biology and translational medicine. *Theranostics*. 2018;8:237–55.
  29. Hazawa M, Tomiyama K, Saotome-Nakamura A, Obara C, Yasuda T, Gotoh T, et al. Radiation increases the cellular uptake of exosomes through CD29/CD81 complex formation. *Biochem Biophys Res Commun*. 2014;446:1165–71.
  30. Grosso S, Doyen J, Parks SK, Bertero T, Paye A, Cardinaud B, et al. MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. *Cell Death Dis*. 2013;4:e544.
  31. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). *J Biol Chem*. 1987;262:9412–20.
  32. Lässer C, Alikhani VS, Ekström K, Eldh M, Paredes PT, Bossios A, et al. Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages. *J Transl Med*. 2011;9:9.
  33. Street JM, Barran PE, Mackay CL, Weidt S, Balmforth C, Walsh TS, et al. Identification and proteomic profiling of exosomes in human cerebrospinal fluid. *J Transl Med*. 2012;10:5.
  34. Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. *Biochim Biophys Acta*. 2012;1820:940–8.
  35. Pan BT, Teng K, Wu C, Adam M, Johnstone RM. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. *J Cell Biol*. 1985;101:942–8.
  36. van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. *Nat Rev Mol Cell Biol*. 2018;19:213–28.
  37. Zhang X, Yuan X, Shi H, Wu L, Qian H, Xu W. Exosomes in cancer: small particle, big player. *J Hematol Oncol*. 2015;8:83.
  38. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, et al. B lymphocytes secrete antigen-presenting vesicles. *J Exp Med*. 1996;183:1161–72.
  39. Yuana Y, Koning RI, Kuil ME, Rensen PC, Koster AJ, Bertina RM, et al. Cryo-electron microscopy of extracellular vesicles in fresh plasma. *J Extracell Vesicles*. 2013;2.
  40. Höög JL, Lötval J. Diversity of extracellular vesicles in human ejaculates revealed by cryo-electron microscopy. *J Extracell Vesicles*. 2015;4:28680.
  41. Zabeo D, Cvjetkovic A, Lässer C, Schorb M, Lötval J, Höög JL. Exosomes purified from a single cell type have diverse morphology. *J Extracell Vesicles*. 2017;6:1329476.
  42. Thery C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and Update of the MISEV2014 guidelines. *J Extracell Vesicles*. 2018;7:1535750.
  43. Kanemoto S, Nitani R, Murakami T, Kaneko M, Asada R, Matsuhisa K, et al. Multivesicular body formation enhancement and exosome release during endoplasmic reticulum stress. *Biochem Biophys Res Commun*. 2016;480:166–72.
  44. Thery C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. *Curr Protoc Cell Biol*. 2006;3:3.22.
  45. Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. *J Mol Med (Berl)*. 2013;91:431–7.
  46. Ostrowski M, Carmo NB, Krumeich S, Fanget I, Raposo G, Savina A, et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. *Nat Cell Biol*. 2010;12:19–30 sup pp 1–13.
  47. Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. *Nat Med*. 2016;22:1502.
  48. Mathieu M, Martin-Jaular L, Lavieu G, Théry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. *Nat Cell Biol*. 2019;21:9–17.
  49. Ferguson SW, Nguyen J. Exosomes as therapeutics: the implications of molecular composition and exosomal heterogeneity. *J Control Release*. 2016;228:179–90.
  50. Guescini M, Genedani S, Stocchi V, Agnati LF. Astrocytes and glioblastoma cells release exosomes carrying mtDNA. *J Neural Transm (Vienna)*. 2010;117:1–4.
  51. Keerthikumar S, Chisanga D, Ariyaratne D, Al Saffar H, Anand S, Zhao K, et al. ExoCarta: a web-based compendium of Exosomal cargo. *J Mol Biol*. 2016;428:688–92.
  52. Li S, Li Y, Chen B, Zhao J, Yu S, Tang Y, et al. exoRBase: a database of circRNA, lncRNA and mRNA in human blood exosomes. *Nucleic Acids Res*. 2018;46:D106–12.
  53. Liu T, Zhang Q, Zhang J, Li C, Miao YR, Lei Q, et al. EVmiRNA: a database of miRNA profiling in extracellular vesicles. *Nucleic Acids Res*. 2019;47:D89–93.
  54. Wubbolts R, Leckie RS, Veenhuizen PT, Schwarzmann G, Möbius W, Hoernschmeyer J, et al. Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. *J Biol Chem*. 2003;278:10963–72.
  55. Choi DS, Kim DK, Kim YK, Ghoo YS. Proteomics of extracellular vesicles: exosomes and ectosomes. *Mass Spectrom Rev*. 2015;34:474–90.
  56. Li W, Li C, Zhou T, Liu X, Liu X, Li X, et al. Role of exosomal proteins in cancer diagnosis. *Mol Cancer*. 2017;16:145.
  57. Bellingham SA, Coleman BM, Hill AF. Small RNA deep sequencing reveals a distinct miRNA signature released in exosomes from prion-infected neuronal cells. *Nucleic Acids Res*. 2012;40:10937–49.
  58. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. *Science*. 2008;319:1244–7.
  59. Subra C, Laulagnier K, Perret B, Record M. Exosome lipidomics unravels lipid sorting at the level of multivesicular bodies. *Biochimie*. 2007;89:205–12.
  60. Cong W, Niu C, Lv L, Ni M, Ruan D, Chi L, et al. Metallothionein prevents age-associated cardiomyopathy via inhibiting NF- $\kappa$ B pathway activation and associated Nitrate damage to 2-OGD. *Antioxid Redox Signal*. 2016;25:936–52.
  61. Lu FB, Chen DZ, Chen L, Hu ED, Wu JL, Li H, et al. Attenuation of experimental autoimmune hepatitis in mice with bone mesenchymal stem cell-derived exosomes carrying MicroRNA-223-3p. *Mol Cells*. 2019;42:906–18.
  62. Du W, Zhang K, Zhang S, Wang R, Nie Y, Tao H, et al. Enhanced proangiogenic potential of mesenchymal



- stem cell-derived exosomes stimulated by a nitric oxide releasing polymer. *Biomaterials*. 2017;133:70–81.
63. Liu W, Li L, Rong Y, Qian D, Chen J, Zhou Z, *et al*. Hypoxic mesenchymal stem cell-derived exosomes promote bone fracture healing by the transfer of miR-126. *Acta Biomater*. 2020;103:196–212.
  64. Zhang Y, Liu Y, Liu H, Tang WH. Exosomes: biogenesis, biologic function and clinical potential. *Cell Biosci*. 2019;9:19.
  65. Salehi M, Sharifi M. Exosomal miRNAs as novel cancer biomarkers: challenges and opportunities. *J Cell Physiol*. 2018;233:6370–80.
  66. Jin X, Chen Y, Chen H, Fei S, Chen D, Cai X, *et al*. Evaluation of tumor-derived Exosomal miRNA as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing. *Clin Cancer Res*. 2017;23:5311–9.
  67. Rastogi S, Sharma V, Bharti PS, Rani K, Modi GP, Nikolajeff F, *et al*. The evolving landscape of exosomes in neurodegenerative diseases: exosomes characteristics and a promising role in early diagnosis. *Int J Mol Sci*. 2021;22:440.
  68. Zamani P, Fereydouni N, Butler AE, Navashenaq JG, Sahebkar A. The therapeutic and diagnostic role of exosomes in cardiovascular diseases. *Trends Cardiovasc Med*. 2019;29:313–23.
  69. Sahoo S, Adamiak M, Mathiyalagan P, Kenneweg F, Kafert-Kasting S, Thum T. Therapeutic and diagnostic translation of extracellular vesicles in cardiovascular diseases: roadmap to the clinic. *Circulation*. 2021;143:1426–49.
  70. Masyuk AI, Masyuk TV, Larusso NF. Exosomes in the pathogenesis, diagnostics and therapeutics of liver diseases. *J Hepatol*. 2013;59:621–5.
  71. Zhang W, Zhou X, Zhang H, Yao Q, Liu Y, Dong Z. Extracellular vesicles in diagnosis and therapy of kidney diseases. *Am J Physiol Renal Physiol*. 2016;311:F844–51.
  72. Alipoor SD, Mortaz E, Garssen J, Movassaghi M, Mirsaedi M, Adcock IM. Exosomes and Exosomal miRNA in respiratory diseases. *Mediators Inflamm*. 2016;2016:5628404.
  73. Zhao M, Juanjuan L, Weijia F, Jing X, Qiuhua H, Hua Z, *et al*. Expression levels of MicroRNA-125b in serum exosomes of patients with asthma of different severity and its diagnostic significance. *Curr Drug Metab*. 2019;20:781–4.
  74. He C, Li L, Wang L, Meng W, Hao Y, Zhu G. Exosome-mediated cellular crosstalk within the tumor microenvironment upon irradiation. *Cancer Biol Med*. 2021;18:21–33.
  75. Luo A, Zhou X, Shi X, Zhao Y, Men Y, Chang X, *et al*. Exosome-derived miR-339-5p mediates radiosensitivity by targeting Cdc25A in locally advanced esophageal squamous cell carcinoma. *Oncogene*. 2019;38:4990–5006.
  76. Kulkarni S, Koller A, Mani KM, Wen R, Alfieri A, Saha S, *et al*. Identifying urinary and serum exosome biomarkers for radiation exposure using a data dependent acquisition and SWATH-MS combined workflow. *Int J Radiat Oncol Biol Phys*. 2016;96:566–77.
  77. Arcsott WT, Tandle AT, Zhao S, Shabason JE, Gordon IK, Schlaff CD, *et al*. Ionizing radiation and glioblastoma exosomes: implications in tumor biology and cell migration. *Transl Oncol*. 2013;6:638–IN6.
  78. Lehmann BD, Paine MS, Brooks AM, McCubrey JA, Renegar RH, Wang R, *et al*. Senescence-associated exosome release from human prostate cancer cells. *Cancer Res*. 2008;68:7864–71.
  79. Jelonek K, Widlak P, Pietrowska M. The influence of ionizing radiation on exosome composition, secretion and intercellular communication. *Protein Pept Lett*. 2016;23:656–63.
  80. Lespagnol A, Duflaut D, Beekman C, Blanc L, Fiucci G, Marine JC, *et al*. Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice. *Cell Death Differ*. 2008;15:1723–33.
  81. Jella KK, Rani S, O'Driscoll L, McClean B, Byrne HJ, Lyng FM. Exosomes are involved in mediating radiation induced bystander signaling in human keratinocyte cells. *Radiat Res*. 2014;181:138–45.
  82. Al-Mayah A, Bright S, Chapman K, Irons S, Luo P, Carter D, *et al*. The non-targeted effects of radiation are perpetuated by exosomes. *Mutat Res*. 2015;772:38–45.
  83. Bagheri HS, Mousavi M, Rezaabakhsh A, Rezaie J, Rasta SH, Nourazarian A, *et al*. Low-level laser irradiation at a high power intensity increased human endothelial cell exosome secretion via Wnt signaling. *Lasers Med Sci*. 2018;33:1131–45.
  84. Agarwal K, Saji M, Lazaroff SM, Palmer AF, Ringel MD, Paulaitis ME. Analysis of exosome release as a cellular response to MAPK pathway inhibition. *Langmuir*. 2015;31:5440–8.
  85. Jelonek K, Wojakowska A, Marczak L, Muer A, Tinhofe-Keilholz I, Lysek-Gladysinska M, *et al*. Ionizing radiation affects protein composition of exosomes secreted in vitro from head and neck squamous cell carcinoma. *Acta Biochim Pol*. 2015;62:265–72.
  86. Shen Z, Sun J, Shao J, Xu J. Ultraviolet B irradiation enhances the secretion of exosomes by human primary melanocytes and changes their exosomal miRNA profile. *PLoS One*. 2020;15:e0237023.
  87. Schae D, McBride WH. Opportunities and challenges of radiotherapy for treating cancer. *Nat Rev Clin Oncol*. 2015;12:527–40.
  88. Mallegol J, Van Niel G, Lebreton C, Lepelletier Y, Candalh C, Dugave C, *et al*. T84-intestinal epithelial exosomes bear MHC class II/peptide complexes potentiating antigen presentation by dendritic cells. *Gastroenterology*. 2007;132:1866–76.
  89. Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, *et al*. Tumour exosome integrins determine organotropic metastasis. *Nature*. 2015;527:329–35.
  90. Prise KM, Saran A. Concise review: stem cell effects in radiation risk. *Stem Cells*. 2011;29:1315–21.
  91. Sha J, Arbesman J, Harter ML. Premature senescence in human melanocytes after exposure to solar UVR: An exosome and UV-miRNA connection. *Pigment Cell Melanoma Res*. 2020;33:671–84.
  92. Marcu LG. Altered fractionation in radiotherapy: from radiobiological rationale to therapeutic gain. *Cancer Treat Rev*. 2010;36:606–14.
  93. Ryan JL. Ionizing radiation: the good, the bad, and the ugly. *J Invest Dermatol*. 2012;132:985–93.
  94. Horton JA, Hudak KE, Chung EJ, White AO, Scroggins BT, Burkeen JF, *et al*. Mesenchymal stem cells inhibit cutaneous radiation-induced fibrosis by suppressing chronic inflammation. *Stem Cells*. 2013;31:2231–41.
  95. Bray FN, Simmons BJ, Wolfson AH, Nouri K. Acute and chronic cutaneous reactions to ionizing radiation therapy. *Dermatol Ther (Heidelb)*. 2016;6:185–206.
  96. Spalek M. Chronic radiation-induced dermatitis: challenges and solutions. *Clin Cosmet Investig Dermatol*. 2016;9:473–82.

97. Suárez B, López-Abente G, Martínez C, Navarro C, Tormo MJ, Rosso S, *et al.* Occupation and skin cancer: the results of the HELIOS-I multicenter case-control study. *BMC Public Health*. 2007;7:180.
98. Karagas MR, Nelson HH, Zens MS, Linet M, Stukel TA, Spencer S, *et al.* Squamous cell and basal cell carcinoma of the skin in relation to radiation therapy and potential modification of risk by sun exposure. *Epidemiology*. 2007;18:776–84.
99. Martin MT, Vulin A, Hendry JH. Human epidermal stem cells: role in adverse skin reactions and carcinogenesis from radiation. *Mutat Res*. 2016;770:349–68.
100. McDougall S, Dallon J, Sherratt J, Maini P. Fibroblast migration and collagen deposition during dermal wound healing: mathematical modelling and clinical implications. *Philos Trans A Math Phys Eng Sci*. 2006;364:1385–405.
101. Bae YU, Son Y, Kim CH, Kim KS, Hyun SH, Woo HG, *et al.* Embryonic stem cell-derived mmu-miR-291a-3p inhibits cellular senescence in human dermal fibroblasts through the TGF- $\beta$  receptor 2 pathway. *J Gerontol A Biol Sci Med Sci*. 2019;74:1359–67.
102. Galvez-Martín P, Martín JM, Ruiz AM, Clares B. Encapsulation in cell therapy: methodologies, materials, and clinical applications. *Curr Pharm Biotechnol*. 2017;18:365–77.
103. Maguire G. Stem cell therapy without the cells. *Commun Integr Biol*. 2013;6:e26631.
104. Morrison TJ, Jackson MV, Cunningham EK, Kissenpfennig A, McAuley DF, O’Kane CM, *et al.* Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer. *Am J Respir Crit Care Med*. 2017;196:1275–86.
105. Gao S, Chen T, Hao Y, Zhang F, Tang X, Wang D, *et al.* Exosomal miR-135a derived from human amnion mesenchymal stem cells promotes cutaneous wound healing in rats and fibroblast migration by directly inhibiting LATS2 expression. *Stem Cell Res Ther*. 2020;11:56.
106. Tao SC, Guo SC, Li M, Ke QF, Guo YP, Zhang CQ. Chitosan wound dressings incorporating exosomes derived from MicroRNA-126-overexpressing synovium mesenchymal stem cells provide sustained release of exosomes and heal full-thickness skin defects in a diabetic rat model. *Stem Cells Transl Med*. 2017;6:736–47.
107. Wang T, Jian Z, Baskys A, Yang J, Li J, Guo H, *et al.* MSC-derived exosomes protect against oxidative stress-induced skin injury via adaptive regulation of the NRF2 defense system. *Biomaterials*. 2020;257:120264.
108. Liu H, Liang Z, Wang F, Zhou C, Zheng X, Hu T, *et al.* Exosomes from mesenchymal stromal cells reduce murine colonic inflammation via a macrophage-dependent mechanism. *JCI Insight*. 2019;4:e131273.
109. Domenis R, Cifù A, Quaglia S, Pistis C, Moretti M, Vicario A, *et al.* Pro inflammatory stimuli enhance the immunosuppressive functions of adipose mesenchymal stem cells-derived exosomes. *Sci Rep*. 2018;8:13325.
110. Vergadi E, Vaporidi K, Theodorakis EE, Doxaki C, Lagoudaki E, Ieronymaki E, *et al.* Akt2 deficiency protects from acute lung injury via alternative macrophage activation and miR-146a induction in mice. *J Immunol*. 2014;192:394–406.
111. Jiang P, Liu R, Zheng Y, Liu X, Chang L, Xiong S, *et al.* MiR-34a inhibits lipopolysaccharide-induced inflammatory response through targeting Notch1 in murine macrophages. *Exp Cell Res*. 2012;318:1175–84.
112. Jiang X, Jiang X, Qu C, Chang P, Zhang C, Qu Y, *et al.* Intravenous delivery of adipose-derived mesenchymal stromal cells attenuates acute radiation-induced lung injury in rats. *Cytotherapy*. 2015;17:560–70.
113. Zuo R, Liu M, Wang Y, Li J, Wang W, Wu J, *et al.* BM-MSC-derived exosomes alleviate radiation-induced bone loss by restoring the function of recipient BM-MSCs and activating Wnt/ $\beta$ -catenin signaling. *Stem Cell Res Ther*. 2019;10:30.
114. Gan F, Wang R, Lyu P, Li Y, Fu R, Du Y, *et al.* Plasma-derived exosomes boost the healing of irradiated wound by regulating cell proliferation and Ferroptosis. *J Biomed Nanotechnol*. 2021;17:100–14.
115. Hu S, Li Z, Cores J, Huang K, Su T, Dinh PU, *et al.* Needle-free injection of exosomes derived from human dermal fibroblast spheroids ameliorates skin Photoaging. *ACS Nano*. 2019;13:11273–82.
116. Liang JX, Liao X, Li SH, Jiang X, Li ZH, Wu YD, *et al.* Antiaging properties of exosomes from adipose-derived mesenchymal stem cells in Photoaged rat skin. *Biomed Res Int*. 2020;2020:6406395.
117. Morgan WF, Sowa MB. Non-targeted effects induced by ionizing radiation: mechanisms and potential impact on radiation induced health effects. *Cancer Lett*. 2015;356:17–21.
118. Tan W, Zhang Y, Li M, Zhu X, Yang X, Wang J, *et al.* miR-27a-contained exosomes secreted by irradiated skin keratinocytes delayed the migration of Unirradiated skin fibroblasts. *Int J Biol Sci*. 2019;15:2240–55.
119. Ni N, Ma W, Tao Y, Liu J, Hua H, Cheng J, *et al.* Exosomal MiR-769-5p exacerbates ultraviolet-induced bystander effect by targeting TGFBR1. *Front Physiol*. 2020;11:603081.
120. Trott KR, Herrmann T, Kasper M. Target cells in radiation pneumopathy. *Int J Radiat Oncol Biol Phys*. 2004;58:463–9.
121. Nagarajan D, Melo T, Deng Z, Almeida C, Zhao W. ERK/GSK3 $\beta$ /snail signaling mediates radiation-induced alveolar epithelial-to-mesenchymal transition. *Free Radic Biol Med*. 2012;52:983–92.
122. Giuranno L, Ient J, De Ruyscher D, Vooijs MA. Radiation-induced lung injury (RILI). *Front Oncol*. 2019;9:877.
123. Ding NH, Li JJ, Sun LQ. Molecular mechanisms and treatment of radiation-induced lung fibrosis. *Curr Drug Targets*. 2013;14:1347–56.
124. Xia C, Chang P, Zhang Y, Shi W, Liu B, Ding L, *et al.* Therapeutic effects of bone marrow-derived mesenchymal stem cells on radiation-induced lung injury. *Oncol Rep*. 2016;35:731–8.
125. Xu S, Liu C, Ji HL. Concise review: therapeutic potential of the mesenchymal stem cell derived Secretome and extracellular vesicles for radiation-induced lung injury: progress and hypotheses. *Stem Cells Transl Med*. 2019;8:344–54.
126. Epperly MW, Guo H, Grettton JE, Greenberger JS. Bone marrow origin of myofibroblasts in irradiation pulmonary fibrosis. *Am J Respir Cell Mol Biol*. 2003;29:213–24.
127. Rubin P, Johnston CJ, Williams JP, McDonald S, Finkelstein JN. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. *Int J Radiat Oncol Biol Phys*. 1995;33:99–109.
128. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. *Nat Rev Mol Cell Biol*. 2002;3:349–63.

129. Pardo A, Selman M. Matrix metalloproteases in aberrant fibrotic tissue remodeling. *Proc Am Thorac Soc.* 2006;3:383–8.
130. Meziani L, Mondini M, Petit B, Boissonnas A, Thomas de Montpreville V, Mercier O, et al. CSF1R inhibition prevents radiation pulmonary fibrosis by depletion of interstitial macrophages. *Eur Respir J.* 2018;51:1702120.
131. Abernathy LM, Fountain MD, Rothstein SE, David JM, Yunker CK, Rakowski J, et al. Soy Isoflavones promote radioprotection of normal lung tissue by inhibition of radiation-induced activation of macrophages and neutrophils. *J Thorac Oncol.* 2015;10:1703–12.
132. Huang Y, Zhang W, Yu F, Gao F. The cellular and molecular mechanism of radiation-induced lung injury. *Med Sci Monit.* 2017;23:3446–50.
133. Park HR, Jo SK, Jung U. Ionizing radiation promotes epithelial-to-mesenchymal transition in lung epithelial cells by TGF- $\beta$ -producing M2 macrophages. *In Vivo.* 2019;33:1773–84.
134. Denham JW, Hauer-Jensen M. The radiotherapeutic injury—a complex 'wound'. *Radiother Oncol.* 2002;63:129–45.
135. Wynn TA. Integrating mechanisms of pulmonary fibrosis. *J Exp Med.* 2011;208:1339–50.
136. Horie S, Laffey JG. Recent insights: mesenchymal stromal/stem cell therapy for acute respiratory distress syndrome. *F1000Res.* 2016;5: F1000 Faculty Rev-1532.
137. Bury MI, Fuller NJ, Wethekam L, Sharma AK. Bone marrow derived cells facilitate urinary bladder regeneration by attenuating tissue inflammatory responses. *Cent European J Urol.* 2015;68:115–20.
138. Xue J, Li X, Lu Y, Gan L, Zhou L, Wang Y, et al. Gene-modified mesenchymal stem cells protect against radiation-induced lung injury. *Mol Ther.* 2013;21:456–65.
139. Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. *Proc Natl Acad Sci U S A.* 2007;104:11002–7.
140. Zhang B, Yin Y, Lai RC, Tan SS, Choo AB, Lim SK. Mesenchymal stem cells secrete immunologically active exosomes. *Stem Cells Dev.* 2014;23:1233–44.
141. Xiong S, Pan X, Xu L, Yang Z, Guo R, Gu Y, et al. Regulatory T cells promote  $\beta$ -catenin-mediated epithelium-to-mesenchyme transition during radiation-induced pulmonary fibrosis. *Int J Radiat Oncol Biol Phys.* 2015;93:425–35.
142. Blazquez R, Sanchez-Margallo FM, de la Rosa O, Dalemans W, Alvarez V, Tarazona R, et al. Immunomodulatory potential of human adipose mesenchymal stem cells derived exosomes on in vitro stimulated T cells. *Front Immunol.* 2014;4:556.
143. Moon HG, Cao Y, Yang J, Lee JH, Choi HS, Jin Y. Lung epithelial cell-derived extracellular vesicles activate macrophage-mediated inflammatory responses via ROCK1 pathway. *Cell Death Dis.* 2015;6:e2016.
144. Eldh M, Ekström K, Valadi H, Sjöstrand M, Olsson B, Jernäs M, et al. Exosomes communicate protective messages during oxidative stress; possible role of exosomal shuttle RNA. *PLoS One.* 2010;5:e15353.
145. Tomasik B, Chałubińska-Fendler J, Chowdhury D, Fendler W. Potential of serum microRNAs as biomarkers of radiation injury and tools for individualization of radiotherapy. *Transl Res.* 2018;201:71–83.
146. Shin S, Cha HJ, Lee EM, Lee SJ, Seo SK, Jin HO, et al. Alteration of miRNA profiles by ionizing radiation in A549 human non-small cell lung cancer cells. *Int J Oncol.* 2009;35:81–6.
147. Liu M, Liu L, Bai M, Zhang L, Ma F, Yang X, et al. Hypoxia-induced activation of twist/miR-214/E-cadherin axis promotes renal tubular epithelial cell mesenchymal transition and renal fibrosis. *Biochem Biophys Res Commun.* 2018;495:2324–30.
148. Ti D, Hao H, Fu X, Han W. Mesenchymal stem cells-derived exosomal microRNAs contribute to wound inflammation. *Sci China Life Sci.* 2016;59:1305–12.
149. Saba R, Sorensen DL, Booth SA. MicroRNA-146a: a dominant, negative regulator of the innate immune response. *Front Immunol.* 2014;5:578.
150. Li X, Liu L, Yang J, Yu Y, Chai J, Wang L, et al. Exosome derived from human umbilical cord mesenchymal stem cell mediates MiR-181c attenuating burn-induced excessive inflammation. *EBioMedicine.* 2016;8:72–82.
151. Etzrodt M, Cortez-Retamozo V, Newton A, Zhao J, Ng A, Wildgruber M, et al. Regulation of monocyte functional heterogeneity by miR-146a and Relb. *Cell Rep.* 2012;1:317–24.
152. Ti D, Hao H, Tong C, Liu J, Dong L, Zheng J, et al. LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b. *J Transl Med.* 2015;13:308.
153. Fang S, Xu C, Zhang Y, Xue C, Yang C, Bi H, et al. Umbilical cord-derived mesenchymal stem cell-derived Exosomal MicroRNAs suppress Myofibroblast differentiation by inhibiting the transforming growth factor- $\beta$ /SMAD2 pathway during wound healing. *Stem Cells Transl Med.* 2016;5: 1425–39.
154. Wang B, Yao K, Huuskes BM, Shen HH, Zhuang J, Godson C, et al. Mesenchymal stem cells deliver exogenous MicroRNA-let7c via exosomes to attenuate renal fibrosis. *Mol Ther.* 2016;24:1290–301.
155. Qian X, Xu C, Fang S, Zhao P, Wang Y, Liu H, et al. Exosomal MicroRNAs derived from umbilical mesenchymal stem cells inhibit hepatitis C virus infection. *Stem Cells Transl Med.* 2016;5:1190–203.
156. Yi X, Wei X, Lv H, An Y, Li L, Lu P, et al. Exosomes derived from microRNA-30b-3p-overexpressing mesenchymal stem cells protect against lipopolysaccharide-induced acute lung injury by inhibiting SAA3. *Exp Cell Res.* 2019;383:111454.
157. Williams JP, Brown SL, Georges GE, Hauer-Jensen M, Hill RP, Huser AK, et al. Animal models for medical countermeasures to radiation exposure. *Radiat Res.* 2010;173:557–78.
158. Green DE, Rubin CT. Consequences of irradiation on bone and marrow phenotypes, and its relation to disruption of hematopoietic precursors. *Bone.* 2014;63:87–94.
159. Donaubaer AJ, Deloch L, Becker I, Fietkau R, Frey B, Gaipf US. The influence of radiation on bone and bone cells-differential effects on osteoclasts and osteoblasts. *Int J Mol Sci.* 2020;21:6377.
160. Iaquina MR, Mazzoni E, Bononi I, Rotondo JC, Mazziotta C, Montesi M, et al. Adult stem cells for bone regeneration and repair. *Front Cell Dev Biol.* 2019;7:268.
161. Nanduri LSY, Duddempudi PK, Yang WL, Tamarat R, Guha C. Extracellular vesicles for the treatment of radiation injuries. *Front Pharmacol.* 2021;12:662437.
162. Okamoto K, Nakashima T, Shinohara M, Negishi-Koga T, Komatsu N, Terashima A, et al. Osteoimmunology: the conceptual framework unifying the immune and skeletal systems. *Physiol Rev.* 2017;97:1295–349.
163. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation

- capacity, immunological features, and potential for homing. *Stem Cells*. 2007;25:2739–49.
164. Szymczyk KH, Shapiro IM, Adams CS. Ionizing radiation sensitizes bone cells to apoptosis. *Bone*. 2004;34:148–56.
  165. Wang C, Meng H, Wang X, Zhao C, Peng J, Wang Y. Differentiation of bone marrow mesenchymal stem cells in osteoblasts and adipocytes and its role in treatment of osteoporosis. *Med Sci Monit*. 2016;22:226–33.
  166. Deng Y, Wu S, Zhou H, Bi X, Wang Y, Hu Y, et al. Effects of a miR-31, Runx2, and Satb2 regulatory loop on the osteogenic differentiation of bone mesenchymal stem cells. *Stem Cells Dev*. 2013;22:2278–86.
  167. Li J, Zhang N, Huang X, Xu J, Fernandes JC, Dai K, et al. Dexamethasone shifts bone marrow stromal cells from osteoblasts to adipocytes by C/EBPalpha promoter methylation. *Cell Death Dis*. 2013;4:e832.
  168. Wang Y, Zhu G, Wang J, Chen J. Irradiation alters the differentiation potential of bone marrow mesenchymal stem cells. *Mol Med Rep*. 2016;13:213–23.
  169. Zhang X, Xiang L, Ran Q, Liu Y, Xiang Y, Xiao Y, et al. Crif1 promotes adipogenic differentiation of bone marrow mesenchymal stem cells after irradiation by modulating the PKA/CREB signaling pathway. *Stem Cells*. 2015;33:1915–26.
  170. Hu L, Yin C, Zhao F, Ali A, Ma J, Qian A. Mesenchymal stem cells: cell fate decision to osteoblast or adipocyte and application in osteoporosis treatment. *Int J Mol Sci*. 2018;19:360.
  171. Mianehsaz E, Mirzaei HR, Mahjoubin-Tehran M, Rezaee A, Sahebnaasagh R, Pourhanifeh MH, et al. Mesenchymal stem cell-derived exosomes: a new therapeutic approach to osteoarthritis? *Stem Cell Res Ther*. 2019;10:340.
  172. Cosenza S, Ruiz M, Toupet K, Jorgensen C, Noël D. Mesenchymal stem cells derived exosomes and microparticles protect cartilage and bone from degradation in osteoarthritis. *Sci Rep*. 2017;7:16214.
  173. Lai RC, Yeo RW, Lim SK. Mesenchymal stem cell exosomes. *Semin Cell Dev Biol*. 2015;40:82–8.
  174. Zhang J, Liu X, Li H, Chen C, Hu B, Niu X, et al. Exosomes/tricalcium phosphate combination scaffolds can enhance bone regeneration by activating the PI3K/Akt signaling pathway. *Stem Cell Res Ther*. 2016;7:136.
  175. Qi X, Zhang J, Yuan H, Xu Z, Li Q, Niu X, et al. Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells repair critical-sized bone defects through enhanced angiogenesis and osteogenesis in osteoporotic rats. *Int J Biol Sci*. 2016;12:836–49.
  176. Ekström K, Omar O, Granéli C, Wang X, Vazirisani F, Thomsen P. Monocyte exosomes stimulate the osteogenic gene expression of mesenchymal stem cells. *PLoS One*. 2013;8:e75227.
  177. Xu JF, Yang GH, Pan XH, Zhang SJ, Zhao C, Qiu BS, et al. Altered microRNA expression profile in exosomes during osteogenic differentiation of human bone marrow-derived mesenchymal stem cells. *PLoS One*. 2014;9:e114627.
  178. Wei J, Li H, Wang S, Li T, Fan J, Liang X, et al. Let-7 enhances osteogenesis and bone formation while repressing adipogenesis of human stromal/mesenchymal stem cells by regulating HMGA2. *Stem Cells Dev*. 2014;23:1452–63.
  179. Zhang WB, Zhong WJ, Wang L. A signal-amplification circuit between miR-218 and Wnt/ $\beta$ -catenin signal promotes human adipose tissue-derived stem cells osteogenic differentiation. *Bone*. 2014;58:59–66.
  180. Bhushan R, Grünhagen J, Becker J, Robinson PN, Ott CE, Knaus P. miR-181a promotes osteoblastic differentiation through repression of TGF- $\beta$  signaling molecules. *Int J Biochem Cell Biol*. 2013;45:696–705.
  181. Du Y, Tang H, Gu X, Shi Y, Gong P, Yao Y. Radiation can regulate the expression of miRNAs associated with osteogenesis and oxidation in exosomes from peripheral blood plasma. *Oxid Med Cell Longev*. 2021;2021:6646323.
  182. Behera J, Tyagi N. Exosomes: mediators of bone diseases, protection, and therapeutics potential. *Onco Targets Ther*. 2018;5:181–95.
  183. Zhao L, Jiang S, Hantash BM. Transforming growth factor beta1 induces osteogenic differentiation of murine bone marrow stromal cells. *Tissue Eng Part A*. 2010;16:725–33.
  184. Cui Y, Luan J, Li H, Zhou X, Han J. Exosomes derived from mineralizing osteoblasts promote ST2 cell osteogenic differentiation by alteration of microRNA expression. *FEBS Lett*. 2016;590:185–92.
  185. Zhang J, Tu Q, Bonewald LF, He X, Stein G, Lian J, et al. Effects of miR-335-5p in modulating osteogenic differentiation by specifically downregulating Wnt antagonist DKK1. *J Bone Miner Res*. 2011;26:1953–63.
  186. You L, Gu W, Chen L, Pan L, Chen J, Peng Y. MiR-378 overexpression attenuates high glucose-suppressed osteogenic differentiation through targeting CASP3 and activating PI3K/Akt signaling pathway. *Int J Clin Exp Pathol*. 2014;7:249–61.
  187. Stone HB, Moulder JE, Coleman CN, Ang KK, Anscher MS, Barcellos-Hoff MH, et al. Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI workshop, December 3–4, 2003. *Radiat Res*. 2004;162:711–28.
  188. Kouvaris JR, Kouloulis VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector. *Oncologist*. 2007;12:738–47.
  189. Raviraj J, Bokkasam VK, Kumar VS, Reddy US, Suman V. Radiosensitizers, radioprotectors, and radiation mitigators. *Indian J Dent Res*. 2014;25:83–90.
  190. Singh VK, Seed TM. The efficacy and safety of amifostine for the acute radiation syndrome. *Expert Opin Drug Saf*. 2019;18:1077–90.
  191. King M, Joseph S, Albert A, Thomas TV, Nittala MR, Woods WC, et al. Use of Amifostine for Cytoprotection during radiation therapy: a review. *Oncology*. 2020;98:61–80.
  192. Bhanja P, Norris A, Gupta-Saraf P, Hoover A, Saha S. BCN057 induces intestinal stem cell repair and mitigates radiation-induced intestinal injury. *Stem Cell Res Ther*. 2018;9:26.
  193. Brown M. What causes the radiation gastrointestinal syndrome?: overview. *Int J Radiat Oncol Biol Phys*. 2008;70:799–800.
  194. Lu X, Nurmamet D, Bolduc DL, Elliott TB, Kiang JG. Radioprotective effects of oral 17-dimethylaminoethylamino-17-demethoxygeldanamycin in mice: bone marrow and small intestine. *Cell Biosci*. 2013;3:36.
  195. Saha S, Aranda E, Hayakawa Y, Bhanja P, Atay S, Brodin NP, et al. Macrophage-derived extracellular vesicle-packaged WNTs rescue intestinal stem cells and enhance survival after radiation injury. *Nat Commun*. 2016;7:13096.
  196. Accarie A, et al. Extracellular vesicles derived from mesenchymal stromal cells mitigate intestinal toxicity in a mouse model of acute radiation syndrome. *Stem Cell Res Ther*. 2020;11:371.



197. Rocchi C, Emmerson E. Mouth-watering results: clinical need, current approaches, and future directions for salivary gland regeneration. *Trends Mol Med*. 2020;26:649–69.
198. Burlage FR, Coppes RP, Meertens H, Stokman MA, Vissink A. Parotid and submandibular/sublingual salivary flow during high dose radiotherapy. *Radiother Oncol*. 2001;2001:271–4.
199. Lombaert IM, Brunsting JF, Wierenga PK, Faber H, Stokman MA, Kok T, et al. Rescue of salivary gland function after stem cell transplantation in irradiated glands. *PLoS One*. 2008;3:e2063.
200. Sumita Y, Liu Y, Khalili S, Maria OM, Xia D, Key S, et al. Bone marrow-derived cells rescue salivary gland function in mice with head and neck irradiation. *Int J Biochem Cell Biol*. 2011;43:80–7.
201. Lim JY, Ra JC, Shin IS, Jang YH, An HY, Choi JS, et al. Systemic transplantation of human adipose tissue-derived mesenchymal stem cells for the regeneration of irradiation-induced salivary gland damage. *PLoS One*. 2013;8:e71167.
202. Kordelas L, Rebmann V, Ludwig AK, Radtke S, Ruesing J, Doeppner TR, et al. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. *Leukemia*. 2014;28:970–3.
203. Marbán E. The secret life of exosomes: what bees can teach us about next-generation therapeutics. *J Am Coll Cardiol*. 2018;71:193–200.
204. Xian P, Hei Y, Wang R, Wang T, Yang J, Li J, et al. Mesenchymal stem cell-derived exosomes as a nanotherapeutic agent for amelioration of inflammation-induced astrocyte alterations in mice. *Theranostics*. 2019;9:5956–75.
205. Zhou X, Li Z, Qi M, Zhao P, Duan Y, Yang G, et al. Brown adipose tissue-derived exosomes mitigate the metabolic syndrome in high fat diet mice. *Theranostics*. 2020;10:8197–210.
206. Tian T, Zhang HX, He CP, Fan S, Zhu YL, Qi C, et al. Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. *Biomaterials*. 2018;150:137–49.
207. Bellavia D, Raimondo S, Calabrese G, Forte S, Cristaldi M, Patinella A, et al. Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo chronic myelogenous Leukemia cell growth. *Theranostics*. 2017;7:1333–45.
208. Kojima R, Bojar D, Rizzi G, Hamri GC, El-Baba MD, Saxena P, et al. Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson's disease treatment. *Nat Commun*. 2018;9:1305.
209. Abramowicz A, Łabaj W, Mika J, Szoltysek K, Ślęzak-Prochazka I, Mielańczyk Ł, et al. MicroRNA profile of exosomes and parental cells is differently affected by ionizing radiation. *Radiat Res*. 2020;194:133–42.
210. Jeyaram A, Lamichhane TN, Wang S, Zou L, Dahal E, Kronstadt SM, et al. Enhanced loading of functional miRNA cargo via pH gradient modification of extracellular vesicles. *Mol Ther*. 2020;28:975–85.